Possible value of galectin‐3 on follow‐up of cardiac remodeling during glucocorticoid treatment
Autor: | Yesim Akin, Gokhan Burcin Kubat, Senay Akin, Ümit Güray, Haydar A. Demirel |
---|---|
Rok vydání: | 2021 |
Předmět: |
0301 basic medicine
medicine.medical_specialty Cardiac fibrosis Galectins Health Toxicology and Mutagenesis Type 2 diabetes Toxicology Biochemistry 03 medical and health sciences 0302 clinical medicine Insulin resistance Fibrosis Internal medicine medicine Animals Humans Glucocorticoids Molecular Biology Ventricular Remodeling 030102 biochemistry & molecular biology biology business.industry Blood Proteins General Medicine medicine.disease Insulin receptor Endocrinology Blood pressure Diabetes Mellitus Type 2 Galectin-3 030220 oncology & carcinogenesis Heart failure biology.protein Molecular Medicine Insulin Resistance business |
Zdroj: | Journal of Biochemical and Molecular Toxicology. 35 |
ISSN: | 1099-0461 1095-6670 |
Popis: | Glucocorticoids are among the most prescribed drugs globally due to their potent anti-inflammatory and immunosuppressive properties. Although they have positive effects on the treatment of various disease states; long-term administration is associated with high blood pressure, insulin resistance, and susceptibility to type 2 diabetes. The heart attempts to cope with increased blood pressure and a decrease in glucose utilization by developing pathological cardiac remodeling. However, in this process, cardiac fibrosis formation and deterioration in heart structure and functions occur. Galectin-3, a member of the β-galactoside binding lectins, is consistently associated with inflammation and fibrosis in the pathogenesis of various disease states including insulin resistance and heart failure. Galectin-3 expression is markedly increased in activated macrophages and a subset of activated fibroblasts and vascular cells. Also, failing and remodeling myocardium show increased Gal-3 expression and elevated Gal-3 levels are related to heart failure severity and prognosis. Furthermore, Gal-3-related pathways are recently suggested as therapeutic targets both pharmacologically and genetically to increase insulin sensitivity in vivo. The objective of this review is to provide a summary of our current understanding of the role of glucocorticoid-associated insulin resistance, which is important for some cardiac events, and the potential role of galectin in this pathophysiological process. |
Databáze: | OpenAIRE |
Externí odkaz: |